KYSE520 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Head-Neck cancer cell lines

Organism

Human

Donor History

Squamous cell carcinoma

Growth Properties

Adherent

,

monolayer

Growth Conditions

Culture medium: Ham's F12

,

w: 1.0 mM stable Glutamine

,

w: 1.0 mM Sodium pyruvate

,

w: 1.1 g/L NaHCO3 (Cytion article number 820600a) + RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a); 1:1 mixture. Supplements: Supplement the medium with 2% FBS. Dissociation reagent: Accutase. Seeding density: 0.6 – 1.2 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/KYSE520-Cells/305449

SKU: 305449 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The KYSE520 cell line is a human esophageal squamous cell carcinoma (ESCC) model derived from a primary tumor. It is moderately differentiated and has been instrumental in investigating epithelial-mesenchymal plasticity (EMP) in esophageal cancer. KYSE520 cells exhibit heterogeneity, consisting of both epithelial-like (CD44v+) and mesenchymal-like (CD44v−) subpopulations. These two populations are capable of interconversion, reflecting a dynamic EMP process. This property makes KYSE520 an excellent model for studying cancer stem cell traits and chemoresistance mechanisms in ESCC.

Genetically, KYSE520 cells display notable epigenetic regulation. The promoter region of the JAM3 gene, a tumor suppressor, is unmethylated in these cells, allowing its expression. JAM3 plays a role in regulating cell proliferation, migration, and invasion through Wnt/β-catenin signaling. The maintenance of JAM3 expression in KYSE520 has been linked to the suppression of aggressive cancer phenotypes.

In therapeutic research, KYSE520 cells have been used to explore the role of fibroblast growth factor receptor-like 1 (FGFRL1). Studies have shown that FGFRL1-deficient KYSE520 cells exhibit reduced tumor growth and motility, alongside a decrease in matrix metalloproteinase-1 (MMP-1) and fibroblast growth factor binding protein 1 (FGFBP1) expression. These findings underscore the importance of FGFRL1 in tumorigenesis and suggest potential therapeutic targets. Additionally, the EMP dynamics and associated molecular pathways in KYSE520 cells provide insights into ESCC progression and resistance mechanisms, contributing to the development of targeted treatments.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.